Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer

INTERVENTION: An amount of 600ml/day of enteral nutritional supplement(Racol@ )is administerd for patients who receive chemotherapy consisting of 5‐FU, cisplatin and docetaxel for advanced esophageal cancers are administered.This nutrition intervention is performed for 15 days, from 3 days before the start of chemotherapy to 7 days after the completion of chemotherapy. An amount of 600ml/day of enteral nutritional supplement(Ensure Liquid@ )is administerd for patients who receive chemotherapy consisting of 5‐FU, cisplatin and docetaxel for advanced esophageal cancers are administered.This nutrition intervention is performed for 15 days, from 3 days before the start of chemotherapy to 7 days after the completion of chemotherapy. CONDITION: esophageal cancer PRIMARY OUTCOME: frequency of chemotherapy‐related adverse effects, especially hematotoxicity SECONDARY OUTCOME: frequency of other chemotherapy‐related adverse effects; nutrition status; feasibility of agjuvant chemotherapy INCLUSION CRITERIA: Patients who have primary esophageal cancer which is histologically confirmed ‐Performance status is 0‐2 ‐No serious abnormality in heart, lung, bone marrow, liver, and renal functions ‐obtain informed consent